

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

BOSTON SCIENTIFIC CORP  
Form 8-K  
September 16, 2003

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 15, 2003

BOSTON SCIENTIFIC CORPORATION

-----

(Exact name of registrant as specified in charter)

DELAWARE	1-11083	04-2695240
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission file number)	(IRS employer identification no.)

ONE BOSTON SCIENTIFIC PLACE, NATICK, MASSACHUSETTS 01760-1537  
-----  
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (508) 650-8000

=====

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.

On September 15, 2003, Boston Scientific Corporation (the "Company") issued a press release announcing nine-month results of its TAXUS IV clinical

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

trial. A copy of the release is attached to this report as exhibit 99.1.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(c) Exhibit.

99.1 Press Release issued by Boston Scientific Corporation dated September 15, 2003.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BOSTON SCIENTIFIC CORPORATION

Date: September 16, 2003

By: /s/ Lawrence J. Knopf

-----  
Lawrence J. Knopf  
Vice President and  
Assistant General Counsel